Effects of ezetimibe on the pharmacodynamics and pharmacokinetics of lovastatin

Current Medical Research and Opinion

Volumn 20, Issue 6, 2004, Pages 955-965

  Kosoglou, Teddy ^a   Statkevich, Paul ^a   Meyer, Ingo ^b   Cutler, David L ^a   Musiol, Bernhard ^a   Yang, Bo ^a   Zhu, Yali ^a   Maxwell, Stephen E ^a   Veltri, Enrico P ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b IQVIA   (United States)

Author keywords

Cholesterol lowering drugs; Drug interactions; Ezetimibe; Lovastatin; Pharmacodynamics; Pharmacokinetics; Statins

Indexed keywords

CHOLESTEROL; EZETIMIBE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PARACETAMOL; PLACEBO; TRIACYLGLYCEROL;

ADULT; AREA UNDER THE CURVE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIET; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG TOLERABILITY; FLATULENCE; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; MALE; MYALGIA; PHARMACODYNAMICS; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE;

ADULT; ANTICHOLESTEREMIC AGENTS; AZETIDINES; CHOLESTEROL, LDL; HUMANS; LOVASTATIN; MALE; PLACEBOS; REFERENCE VALUES; SINGLE-BLIND METHOD; UNITED STATES;

EID: 3042593643     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079904125003872     Document Type: Conference Paper

References (27)

1. Altmann SW, Davis HR, Zhu LJ, G et al. Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science 2004;303:1201-4
2. van Heek M, France CF, Compton DS, et al. In vivo metabolism-based discovery of a potent cholesterol absorption inhibitor, SCH58235, in the rat and rhesus monkey through the identification of the active metabolites of SCH48461. J Pharmacol Exp Ther 1997;283:157-63
3. van Heek M, Farley C, Compton DS, et al. Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663. Br J Pharmacol 2000;129:1748-54
4. van Heek M, Farley C, Compton DS, Hoos L, Davis HR. Ezetimibe selectively inhibits intestinal cholesterol absorption in rodents in the presence and absence of exocrine pancreatic function. Br J Pharmacol 2001;34:409-17
5. Sudhop T, Lütjohann D, Kodal A, et al. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation 2002;106:1943-8
6. Knopp RH, Gitter H, Truitt T, et al. Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur Heart J 2003;24:729-41
7. Ezzet F, Krishna G, Wexler D, Statkevich P, Kosoglou T, Batra V. A population pharmacokinetic model that describes multiple peaks due to enterohepatic recirculation of ezetimibe. Clin Ther 2001;23:871-85
8. Bays HE, Moore PB, Drehobl MA, et al. Effectiveness and tolerability of ezetimibe in subjects with primary hypercholesterolemia: pooled analysis of two phase II studies. Clin Ther 2001;23:1209-30
9. Dujovne CA, Ettinger MP, McNeer JF, et al. Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am J Cardiol 2002;90:1092-7
10. Kosoglou T, Meyer 1, Veltri EP, et al. Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin. Br J Clin Pharmacol 2002;54:309-19
11. Kosoglou T, Seiberling M, Statkevich P, et al. Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and atorvastatin. J Am Coll Cardiol 2001;37(Suppl A):229A [abstract]
12. Kosoglou T, Meyer I, Musiol B, et al. Pharmacodynamic interaction between fluvastatin and ezetimibe has favorable clinical implications. Atherosclerosis 2001;2(Suppl):89 [abstract]
13. Ross SD, Allen IE, Connelly JE, et al. Clinical outcomes in statin treatment trials: a meta-analysis. Arch Intern Med 1999;159:1793-802
14. Davis HR Jr, Pula KK, Alton KB, Burrier RE, Watkins RW. The synergistic hypocholesterolemic activity of the potent cholesterol absorption inhibitor, ezetimibe, in combination with 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in dogs. Metabolism 2001;50:1234-41
15. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). J Am Med Assoc 2001;285:2486-97
16. Statkevich P, Zhu Y, Kosoglou T, Affrime MB, Salfi M, Patrick J. Ezetimibe (SCH 58235) does not affect the pharmacokinetics of simvastatin. Clin Pharmacol Ther 2000;67:146 [abstract]
17. Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. New York: Marcel Dekker, Inc; 1982. p. 409-17
18. Stein E. Results of phase I/II clinical trials with ezetimibe, a novel selective cholesterol absorption inhibitor. Eur Heart J 2001;3(Suppl E):E11-6
19. Physician's Desk Reference. MEVACOR tablets (lovastatin) product information. Montvale, NJ: Medical Economics Company, Inc., 1999. p. 1834
20. Ezzet F, Wexler D, Statkevich P, et al. The plasma concentration and LDL-C relationship in patients receiving ezetimibe. J Clin Pharmacol 2001;41:943-9
21. Knopp RH, Retzlaff B, Walden C, Fish B, Buck B, McCann B. One-year effects of increasingly fat-restricted, carbohydrate-enriched diets on lipoprotein levels in free-living subjects (44564E). Proc Soc Exp Biol Med 2000; 225:191-9
22. Zhu Y, Statkevich P, Kosoglou T, Boutros T, Maxwell SE, Patrick J, Batra V. Effect of age on the pharmacokinetics of ezetimibe, a cholesterol absorption inhibitor. AAPS PharmSci Supplement 2000;2:2082 [abstract]
23. Zhu Y, Statkevich P, Kosoglou T, Maxwell SE, Anderson L, Patrick JE, Batra V. Lack of pharmacokinetic interaction between ezetimibe and atorvastatin. Clin Pharmacol Ther 2001;69:68 [abstract]
24. Reyderman L, Statkevich P, Kosoglou T, Pember LJ, Maxwell SE, Caceres M, Batra VK. No pharmacokinetic drug interaction between ezetimibe and either cerivastatin or fluvastatin. AAPS PharmSci Supplement 2001;3(3) [online abstract]. Available from http://www.aapspharmaceutica.com/ search/ abstract_view.asp?id=331
25. Reyderman L, Kosoglou T, Maxwell SE, Boutros T, Pember LJ, Batra VK, Statkevich P. Lack of pharmacokinetic drug interaction between ezetimibe and fenofibrate. AAPS PharmSci Supplement 2001;3(3) [online abstract]. Available from http://www.aapspharmaceutica.com/search/ abstract_view.asp?id=326
26. Reyderman L, Kosoglou T, Statkevich P, et al. No pharmacokinetic drug interaction between ezetimibe and lovastatin. Clin Pharmacol Ther 2001;69:66 [abstract]
27. Kerzner B, Corbelli J, Sharp S, et al. Efficacy and safety of ezetimibe coadministered with lovastatin in primary hypercholesterolemia. Am J Cardiol 2003;91:418-24